Palazestrant

Item number	Size	Manual	Delivery time	Price
TGM-T72945-1mg	1 mg	-	7 - 10 business days*	286.00€
TGM-T72945-5mg	5 mg	-	7 - 10 business days*	707.00€
TGM-T72945-10mg	10 mg	-	7 - 10 business days*	967.00€
TGM-T72945-25mg	25 mg	-	7 - 10 business days*	1,491.00€
TGM-T72945-50mg	50 mg	-	7 - 10 business days*	1,943.00€

If you have any questions, please use our Contact Form.
You can also order by e-mail: info@biomol.com
Larger quantity required? Request bulk

Description: Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor... more

Close menu

Product information "Palazestrant"

Description: Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.Palazestrant inhibits 17b-estradiol (E2), inhibits MCF7 and CAMA-1 cell proliferation, and can be used in breast cancer research. Target: Estrogen/progestogen Receptor. Smiles: C(C(C)(C)F)N1[C@@H](C2=C(C=3C(N2)=CC=CC3)C[C@H]1C)C4=CC=C(OC5CN(CCC)C5)C=C4. References: Parisian AD, et al. Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination. Mol Cancer Ther. 2024 Mar 4,23(3):285-300.

Keywords:	OP1250, OP 1250, OP-1250
Supplier:	TargetMol
Supplier-Nr:	T72945

Properties

Application:	Targets estrogen receptor alpha (ESR1, NR3A1)
MW:	449.6 D
Formula:	C28H36FN3O

Database Information

CAS :	2092925-89-6\| Matching products
KEGG ID :	K08550 \| Matching products

Handling & Safety

Storage:	+4°C
Shipping:	+4°C (International: +4°C)

Caution
Our products are for laboratory research use only: Not for administration to humans!

Information about the product reference will follow. more

Close menu

You will get a certificate here

Go back

Read, write and discuss reviews... more

Close menu

Customer review for "Palazestrant"

Write a review